##semicolon##
jigar sirrozi, fibroz, portal gipertenziya, jigar etishmovchiligi.##submission.citations##
Бакулин Игорь Геннадьевич, Оганезова Инна Андреевна, Скалинская Екатерина Васильевна, Сказываева Екатерина Васильевна цирроз печени и управление рисками осложнений // Терапевтический архив. 2021. №8.
Ивашкин В.Т., Маевская М.В., Жаркова М.С. и соавторы, Клинические рекомендации Российского общества по изучению печени и Российской гастроэнтерологической ассоциации по диагностике и лечению фиброза и цирроза печени и их осложнений, Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(6). С.56–102.
Цуканов В.В., Васютин А.В., Тонких Ю.Л. Бремя цирроза печени в современном мире. Доктор.Ру. 2021; 20(4): 21–25. DOI: 10.31550/1727-2378-2021-20-4-21-25.
Alberts C.J., Clifford G.M., Georges D. et al., Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: A systematic review. Lancet Gastroenterol. Hepatol. 2022. №7, P.724–735.
Asrani, S. K., Devarbhavi, H., Eaton, J., et al. Burden of liver diseases in the world, Journal of hepatology, 2019. 70(1), P. 151-171.
Castillo J., Martinez-Araj O.T., Bartolamej M.R. et al., High prevalence of occult. Hepatitis C virus infection in patients with primary and secondary glomerular nephropathies, Ridney international. 2014. Vol. 86, N 3. P. 619–624.
GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020 Mar;5(3):245-266. doi: 10.1016/S2468-1253(19)30 349-8. Epub 2020 Jan 22. PMID: 31981519; PMCID: PMC7026710.
Ginès P., Krag A., Abraldes J. G., et al., Liver cirrhosis, The Lancet. 2021. 398(10308). P.1359-1376.
Huang CF, Iio E, Jun DW, Ogawa E, Toyoda H, Hsu YC, et al., REAL-C Investigators Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. Hepatol Int. 2019;13:587–598. doi: 10.1007/s120 72-019-09974-z.
Huang D.Q.,Terrault N.A., Tacke F. et al., Global epidemiology of cirrhosis – A etiology, trends and predictions. Nat. Rev. Gastroenterol. Hepatol. 2023. №20, P.388–398.
Jayasekera C.R., Barry M., Roberts L.R., et al., Treating hepatitis C in lower-income countries. N Engl J Med 2014;370(May). P.1869-1871.
Mak LY, Liu K, Chirapongsathorn S, Yew KC, Tamaki N, Rajaram RB, et al. Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions. Nat Rev Gastroenterol Hepatol. 2024;21:834–851. doi: 10.1038/s41575-024-00967-4.
Méndez-Sánchez N, Coronel-Castillo C.E, Ramírez-Mejía M.M. Chronic Hepatitis C Virus Infection, Extrahepatic Disease and the Impact of New Direct-Acting Antivirals. Pathogens. 2024 Apr 19;13 (4). P.339.
Morales R.J., Vargas G. Occult HBV infection: A faceless enemy in liver cancer development viruses, Viruses. 2014. Vol. 6, N 4. P. 1590–1611.
Liu, Y.B.; Chen, M.K. Epidemiology of liver cirrhosis and associated complications: Current knowledge and future directions. World J. Gastroenterol. 2022, 28, 5910–5930.
Papastergiou, V., Lombardi, R., MacDonald, D., Tsochatzis, E. A., Global epidemiology of hepatitis B virus (HBV) infection. Current hepatology reports, 2015; 14. P.171-178.
Pauline Londeix. New treatments for hepatitis C virus: strategies for achieving universal access. Medicins du Monde 2014; 8. P. 7-15.
Ponde, RA (February 2011). «Hidden hazards of HCV transmission». Medical microbiology and immunology 200 (1). P.7–11.
Shiina S, Maikhuu J, Deng Q, Batsaikhan T, Canseco LM, Tobari M, Maruyama H, Nagamatsu H, Alcantara-Payawal D, Gani R, Huang YH, Tanwandee T, Galati G, Kim YJ. Liver disease trends in the Asia-Pacific region for the next 50 years. Clin Mol Hepatol. 2025 Jul;31(3): 671-684. doi: 10.3350/cmh.2025.00 43. Epub 2025 Mar 4. PMID: 40037692; PMCID: PMC 12260636.
Sarin SK, Kumar M, Eslam M, George J, Al Mahtab M, Akbar SMF, et al. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol 2020;5:167-228. Erratum in: Lancet Gastroenterol Hepatol. 2020;5:e2. doi: 10.1016/S2468-1253 (19)30342-5.
Sepanlou, S. G., Safiri, S., Bisignano, C., et al., The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet gastroenterology & hepatology, 2020. 5(3), P. 245-266.
Wang X, Liu H, Qi J, et al., Trends of Mortality in End-Stage Liver Disease - China, 2008-2020. China CDC Wkly. 2023 Jul 28;5(30):657-663.
WHO. Global Health Estimates: Leading Causes of Death. 2021. P.1-6. Available online: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death.
World Health Organization. Global hepatitis report 2024: action for access in low- and middle-income countries. P.2-242.
World Health Organization Factsheet. HepatitisB, №204. July 2014.
World Health Organization. Data and statistics; 2016. P.23-24.
World Health Organization. (2016). Combating hepatitis B and C to reach elimination by 2030: advocacy brief.P.1-3.
World Health Organization. (2016). Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis P.2-5.
World Health Organization Guidelines on Hepatitis B and C Testing. Geneva: 2017. P.101.
World Health Organization. Weekly epidemiological record. 2023, vol. 98 (38). P. 431 - 452.